Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44352 clinical trials with a EudraCT protocol, of which 7379 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (44,352)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

44,352 result(s) found. Displaying page 2,045 of 2,218.

EudraCT Number: 2017-003839-11	Sponsor Protocol Number: 1352_0PBG_2017	Start Date*: 2018-03-05
Sponsor Name:IRCCS Ospedale PedT..trico Bambino Gesù
Full Title: Belimumab for the treatment of frequently relapsing nephrotic syndrome open label phase II trial. BELNEPH STUDY
Medical condition: frequently relapsing nephrotic syndrome
Disease:
Population Age: Children, Adolescents, Under 18		Gender: Male, Female
Trial protocol: IT (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2021-004420-15	Sponsor Protocol Number: M21IDB	Start Date*: 2021-11-30
Sponsor Name:NKI-AVL
Full Title: A Phase 2 clinical study to assess efficacy of Induction ipilimumab/nivolumab to spare the Bladder in urothelial bladder cancer (Indi-Blade)
Medical condition: Urothelial cell carcinoma of the bladder
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NL (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2022-003318-35

Sponsor Protocol Number: VX22-264-101

Start Date*: 2023-09-25

Sponsor Name:Vertex Pharmaceuticals Incorporated

Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus

Medical condition: Type 1 Diabetes Mellitus

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10027433 - Metabolism and nutrition disorders	10012601	Diabetes mellitus	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-002286-17

Sponsor Protocol Number: INCB00928-201

Start Date*: 2022-04-19

Sponsor Name:Incyte Corporation

Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Medical condition: Fibrodysplasia ossificans progressiva

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10010331 - Congenital, familial and genetic disorders	10068715	Fibrodysplasia ossificans progressiva	PT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2022-002673-28	Sponsor Protocol Number: NL82177.078.22	Start Date*: 2023-01-31
Sponsor Name:Erasmus MC
Full Title: Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with fi...
Medical condition: Stage III irresectable or metastatic melanoma treated with first-line ipilimumab-nivolumab
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: NL (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2018-004084-31

Sponsor Protocol Number: 1002-041

Start Date*: 2023-01-23

Sponsor Name:Esperion Therapeutics, Inc.

Full Title: AN OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF BEMPEDOIC ACID IN PEDIATRIC PATIENTS (6 TO 17 YEARS OF AGE) WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Medical condition: HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10027433 - Metabolism and nutrition disorders	10020604	Hypercholesterolemia	LLT
	20.0	10010331 - Congenital, familial and genetic disorders	10054380	Familial hypercholesterolemia	LLT
	20.0	10010331 - Congenital, familial and genetic disorders	10057079	Heterozygous familial hypercholesterolemia	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: ES (Ongoing) DE (Ongoing) NL (Trial now transitioned) DK (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2016-004106-34	Sponsor Protocol Number: Dastop2October17th2016	Start Date*: 2017-03-06
Sponsor Name:Uppsala University Hospital
Full Title: PERSISTENCE OF MAJOR MOLECULAR REMISSION IN CHRONIC MYELOID LEUKEMIA AFTER a second stop of TKI TREATMENT in patients who failed an initial stop attempt: A prospective multicenter study .
Medical condition: Chronic Myeloid Leukemia
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FI (Completed) DK (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2019-004987-23	Sponsor Protocol Number: RAS-Triplet	Start Date*: 2020-05-22
Sponsor Name:UMC Utrecht
Full Title: A Dose-Escalating Phase I/II Study in Patients with RAS-Mutated Metastatic Colorectal Cancer to Investigate Safety and Clinical Activity of the Triple Combination of: MEK-inhibitor binimetinib, Pan...
Medical condition: colorectal cancer
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NL (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2011-001699-20	Sponsor Protocol Number: 042011	Start Date*: 2012-05-18
Sponsor Name:St. Anna Kinderkrebsforschung, GmbH
Full Title: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with LANGERHANS CELL HISTIOCYTOSIS
Medical condition: Langerhans cell histiocytosis
Disease:
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18		Gender: Male, Female
Trial protocol: AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2022-002369-14

Sponsor Protocol Number: CHUB-Psy-PAThforsAUD

Start Date*: 2023-07-20

Sponsor Name:CHU Brugmann

Full Title: Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)cognitive Mechanisms.

Medical condition: Severe Alcohol Use Disorder

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	10037175 - Psychiatric disorders	10001584	Alcohol abuse	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: BE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2019-002409-23

Sponsor Protocol Number: CLN-081-001(REZILIENT1)

Start Date*: 2020-02-27

Sponsor Name:Cullinan Oncology Inc.

Full Title: A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Locally-Advanced or Metastatic Non-Small C...

Medical condition: Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029515	Non-small cell lung cancer recurrent	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: NL (Trial now transitioned) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2016-000871-26

Sponsor Protocol Number: ABC-Trial

Start Date*: 2016-06-16

Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA

Full Title: Studio di Fase II, randomizzato, in aperto, controllato di fattibilit¿ dell¿impiego di doxiciclina nel tumore mammario in stadio precoce

Medical condition: Breast cancer - Stage 1-2 to or Stage 3 that is candidate for primary surgery

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004864	10006213	Breast carcinoma stage I	LLT
	20.1	100000004864	10006215	Breast carcinoma stage III	LLT
	20.0	100000004864	10006214	Breast carcinoma stage II	LLT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2012-005823-34

Sponsor Protocol Number: ING117172

Start Date*: 2013-10-11

Sponsor Name:ViiV Healthcare UK Limited

Full Title: A Phase IIIb, randomized, open-label study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in...

Medical condition: HIV-infection

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	100000004862	10020160	HIV disease	LLT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) ES (Completed) PT (Completed) FR (Ongoing)

Trial results: View results

EudraCT Number: 2017-005108-89

Sponsor Protocol Number: VHIO17002

Start Date*: 2019-01-25

Sponsor Name:Vall d’Hebron Institute of Oncology (VHIO)

Full Title: Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumors.

Medical condition: Subjects with advanced solid tumor

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10065147	Malignant solid tumor	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-001817-35	Sponsor Protocol Number: 111958	Start Date*: 2021-08-04
Sponsor Name:Radboud University Medical Center
Full Title: Suboxone (buprenorphine/naloxone) versus methadone opioid rotation in patients with escalated opioid use and chronic pain: a randomized trial.
Medical condition: Opioid use disorder
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NL (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2019-004294-13

Sponsor Protocol Number: RD.06.SPR.202699

Start Date*: 2020-10-05

Sponsor Name:Galderma S.A.

Full Title: A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis

Medical condition: Prurigo Nodularis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004858	10037084	Prurigo nodularis	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-003091-40

Sponsor Protocol Number: EMN26

Start Date*: 2020-12-04

Sponsor Name: European Myeloma Network – EMN

Full Title: PHASE II STUDY OF IBERDOMIDE (CC220) MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

Medical condition: Newly diagnosed multiple myeloma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10028228	Multiple myeloma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GR (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-000493-15

Sponsor Protocol Number: NVALT30

Start Date*: 2020-08-13

Sponsor Name:Radboud University Medical Center

Full Title: Dose tapering and Early Discontinuation to InCreAse cosT-effectIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1

Medical condition: non-small cell lung cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10027412	Mesotheliomas	HLGT

Population Age: Adults

Gender: Male, Female

Trial protocol: NL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-001928-17

Sponsor Protocol Number: GCT1046-04

Start Date*: 2021-08-13

Sponsor Name:Genmab A/S

Full Title: A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer...

Medical condition: Malignant Solid Tumors - Non Small Cell Lung Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2019-002528-34

Sponsor Protocol Number: HO158

Start Date*: 2020-10-01

Sponsor Name:HOVON Foundation

Full Title: First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow mi...

Medical condition: Chronic Lymphocytic Leukemia

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10009310	CLL	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Trial now transitioned) DK (Trial now transitioned)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Sat Aug 02 09:57:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA